Suritozole

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Suritozole
Suritozole.svg
Systematic (IUPAC) name
5-(3-fluorophenyl)-2,4-dimethyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
Clinical data
Identifiers
110623-33-1 YesY
None
PubChem CID 25431
ChemSpider 23743 N
UNII 3H7H68317X YesY
KEGG D05980 YesY
Chemical data
Formula C10H10FN3S
223.269 g/mol
 N (what is this?)  (verify)

Suritozole (MDL 26,479) is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABAA ion channel complex, but does not have either anxiogenic or convulsant effects, unlike other BZD inverse agonists such as DMCM.[1] It was investigated for the treatment of depression and Alzheimer's disease,[2] but clinical development seems to have been discontinued.

References[edit]

  1. ^ Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM (September 1992). "MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties". Br. J. Pharmacol. 107 (1): 78–86. doi:10.1111/j.1476-5381.1992.tb14466.x. PMC 1907590. PMID 1330168. 
  2. ^ Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava VO, Weir SJ (May 1997). "Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers". Biopharm Drug Dispos 18 (4): 325–34. doi:10.1002/(SICI)1099-081X(199705)18:4<325::AID-BDD21>3.0.CO;2-1. PMID 9158880.